Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5576201

Title:Retroviral vector particles for transducing non-proliferating cells
Inventors:Mason, James M.; Wallingford, CT, USA
Kennedy, Scott P.; Southington, CT, USA
Summary:This invention describes retroviral vector particles comprising an oncoretroviral gag capsid protein, and methods of their use in transducing non-proliferating cells. Described herein are properties of retroviral vector particles which contain at least one exogenous gene in combination with oncoretroviral gag, pol, and env proteins including an oncoretroviral gag capsid protein which has been mutated so as to contain a nuclear localization signal (NLS) sequence. Further disclosed are methods by which the particles can be used to transduce non-proliferating cells, including stem cells and neurons such that the presence of the NLS sequence allows at least one exogenous gene to enter into the nucleus of a target cell, thereby allowing integration of the gene into the genome of the target cell. This invention represents a continuation of other applications filed by the same assignee and inventors.
Abstract:Retroviral vector particles are provided which contain: 1) oncoretroviral gag, pol, and env proteins, including an oncoretroviral gag matrix protein which has been mutated so as to contain a nuclear localization signal (NLS) sequence; and 2) at least one exogenous gene. The particles can be used to transduce non-proliferating cells, including stem cells and neurons. The presence of the NLS sequence allows the at least one exogenous gene to enter into the nucleus of a target cell, thus allowing integration of the gene into the genome of the target cell.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5576201
Application Number:US1994000182612
Date Filed:14/01/1994
Date Published:19/11/1996
Assignee:Alexion Pharmaceuticals, Inc., New Haven, CT, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/14/2020